Leverage our omni-channel approach to grow your brand across Asia Pacific.
We seek to advance highly specialised and scientifically valuable fields to elevate the standard of healthcare.
Discover more about Menarini Group
For over 30 years, Menarini has been driving research and development to deliver innovative and effective medicines and healthcare solutions for patients affected by serious health conditions.
Gain a single point of entry to all major APAC markets with a direct presence in 13 key markets.
Sharing your partnering idea
Leverage our omni-channel approach to grow your brand across Asia Pacific.
Global Responsibility
FOLLOW US
Global Press Releases
FOLLOW US
MARKETS
The healthcare sector in Asia Pacific is rapidly growing. As part of the world’s leading Italian biopharmaceutical company, Menarini AP has a strong presence in 13 key markets across the region.
As a partner of choice for numerous global healthcare companies, we engage in the entire pharmaceutical development lifecycle to tap growth opportunities and grow their brand footprint. In doing so, we also support healthcare professionals and patients with quality medical products and technology to raise standards and invigorate lives for tomorrow.
Our APAC Headquarters
A. MENARINI ASIA-PACIFIC HOLDINGS PTE LTD
A. MENARINI ASIA-PACIFIC PRIVATE LIMITED
A. MENARINI SINGAPORE PTE LTD
A. MENARINI BIOMARKERS SINGAPORE PTE LTD
30 Pasir Panjang Road,
Mapletree Business City,
#08-32 Singapore 117440
Tel: +65-6494-7200
Fax: +65-6999-1787
- Elem1
- Elem2
- Elem2
- Elem2
- Elem2
OUR FOCUS AREAS
NEWS
-
2023 - 07 - 21
Menarini Group Receives Positive CHMP Opinion Recommending EC Approval of ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation
Each year in Europe more than 550,000 patients are diagnosed with breast cancer, of whom 70% have estrogen receptor (ER)-positive disease¹; more than 147,000 breast cancer patients in Europe die annually from the disease² -
2023 - 09 - 20
European Commission Approves Menarini Group’s ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation
Each year in Europe more than 550,000 patients are diagnosed with breast cancer, of whom 70% have estrogen receptor (ER)-positive disease¹; more than 147,000 breast cancer patients in Europe die annually from the disease² -
2023 - 06 - 20
Fair Play Menarini International Awards announces the winners of the XXVII edition at CONI
ROME, June 19th, 2023 - The winners of the XXVII annual Fair Play Menarini International Awards are no longer a secret. This morning at the CONI Hall of Honour, a press conference was held to present the 2023 edition of the awards, scheduled from July 3rd to 5th in Florence and Fiesole.
